A Look at Mineralys Therapeutics (MLYS) Valuation After Findell Capital's Major New Investment [Yahoo! Finance]
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Mineralys Therapeutics (NASDAQ:MLYS) had its price target raised by analysts at HC Wainwright from $52.00 to $56.00. They now have a "buy" rating on the stock.
Mineralys Therapeutics (NASDAQ:MLYS) had its price target raised by analysts at Wells Fargo & Company from $50.00 to $55.00. They now have an "overweight" rating on the stock.